Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or via email at Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, by telephone at (833) 297-2926 or by email at or Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attention: Prospectus Department, by telephone at (800) 747-3924, or by email at continues A final prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering have been filed with the SEC and are available on the SEC’s website at Copies of the final prospectus supplement and accompanying base prospectus may also be obtained from: J.P.
#Day one biopharmaceuticals registration
The offering was made only by means of a prospectus and prospectus supplement that form a part of the registration statement. The securities were offered by Day One pursuant to a registration statement on Form S-3 previously filed and declared effective by the Securities and Exchange Commission (SEC). Wedbush PacGrow acted as the lead manager for the offering. Morgan, Cowen and Piper Sandler acted as the joint book-running managers for the offering. The gross proceeds to Day One from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $172.5 million. All shares of common stock were offered by Day One.
#Day one biopharmaceuticals full
(Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the closing on Jof its previously announced upsized underwritten public offering of 11,500,000 shares of its common stock, including the full exercise of the underwriters’ option to purchase 1,500,000 additional shares, at a public offering price of $15.00 per share.
SOUTH SAN FRANCISCO, Calif., J(GLOBE NEWSWIRE) - Day One Biopharmaceuticals, Inc.
0 kommentar(er)
